Evidence map›Paper›PMID 42561946›Full record

Trial reportCell reports. Medicine2026

Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.

Tam Binh V Bui, Denise M Wolf, Michael C Bruck, Kaitlin Moore, Jessica Lien, Sarah D W Choi, Shruti Warhadpande, Amirabbas Parizadeh, Deborah Dillon, Beth Overmoyer and 11 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Tam Binh V BuiDepartment of Laboratory Medicine, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA; Molecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands; Oncode Institute, 3521 AL Utrecht, the Netherlands.
Denise M WolfDepartment of Laboratory Medicine, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Michael C BruckDepartment of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Kaitlin MooreDivision of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Jessica LienDepartment of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Sarah D W ChoiDepartment of Surgery, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Shruti WarhadpandeDepartment of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Amirabbas ParizadehDepartment of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Deborah DillonDepartment of Pathology, Brigham & Women's Hospital, Boston, MA 02215, USA.
Beth OvermoyerDivision of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Filipa LynceDivision of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Lamorna Brown-SwigartDepartment of Laboratory Medicine, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Gillian L HirstDepartment of Surgery, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Christina YauDepartment of Surgery, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
I-SPY2 Investigators
Isaac J NijmanUSEQ, Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Boudewijn M T BurgeringMolecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands; Oncode Institute, 3521 AL Utrecht, the Netherlands.
Isaac S HarrisDepartment of Biomedical Genetics, Wilmot Cancer Institute, Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Laura J EssermanDepartment of Surgery, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Laura J van 't VeerDepartment of Laboratory Medicine, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: laura.vantveer@ucsf.edu.
Jennifer M RosenbluthDepartment of Medicine, Division of Hematology & Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA; Division of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Chan Zuckerberg Biohub - San Francisco, San Francisco, CA 94158, USA. Electronic address: jennifer.rosenbluth@ucsf.edu.

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1M
In vitro models as a window to learn how to change outcomes in women at high risk of developing breast cancerR01CA281361 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENBLUTH, JENNIFER M. · 2022 to 2025
$2.7M
NCI NIH HHS P50 CA168504NCI NIH HHS R01 CA281361
6 · The paper itself

Abstract

Poor therapeutic response in subsets of breast cancer (BC) patients poses an ongoing challenge. Here, we present a biomarker-guided characterization of 40 patient-derived BC organoids, with the aim of modeling resistant disease with greater fidelity and developing an in vitro system grounded in clinical data for testing alternative treatment strategies. We utilize patient data from the I-SPY2 clinical trial (NCT01042379) to develop predictive models of response to a range of therapies, using only organoid-detectable biomarkers as input, and validate a model predicting response to veliparib-platinum chemotherapy (VP) in triple-negative BC (TNBC) organoids. A drug screen in VP-resistant TNBC organoids reveals combination treatments that overcome resistance to cisplatin, including pro-apoptotic therapies. Another class of hits, HSP90 inhibitors, links organoid drug sensitivity to improved recurrence-free survival in a biomarker-defined patient subset. These findings establish organoid-based functional modeling as a bridge between clinical biomarkers and precision treatment strategies in breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsOrganoidsTriple Negative Breast NeoplasmsAntineoplastic AgentsDrug Resistance, NeoplasmDrug Screening Assays, AntitumorFemaleHumansAntineoplastic AgentsBiomarkers, Tumorbiomarkersdrug screeningI-SPY2patient-derived organoidstherapy resistancetriple-negative breast cancer

Identifiers

PMID42561946
PMCPMC13522806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.